Drugs Made in America AcquisDMIIU
13F holders, Q1 2026 (March 31)14holders −16
1new positions
5sold out
$9.99avg. 13F price*
At the end of Q1 2026, 14 institutions reported holding Drugs Made in America Acquis (DMIIU) in their 13F filings, down 16 from Q4 2025. 1 opened new positions and 5 sold out. The largest holders were LMR Partners LLP ($20.1M), Westchester Capital Management, LLC ($5.0M) and TIG Advisors, LLC ($5.0M).
- Company
- Drugs Made in America Acquis
- CUSIP
- G2851K120
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $2.1M |
| Exits | 5 | $4.5M |
All 13F filers, Q4 2025 → Q1 2026: 233,061 shares bought and 658,169 shares sold, net −425,108 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 14 holders
| LMR Partners LLP | 0.24% | No change | 2,000,000 | $20.1M |
| Westchester Capital Management, LLC | 0.24% | No change | 502,914 | $5.0M |
| TIG Advisors, LLC | 0.24% | No change | 500,000 | $5.0M |
| BlueCrest Capital Management Ltd | 0.34% | No change | 250,000 | $2.5M |
| Verition Fund Management LLC | 0.03% | No change | 250,000 | $2.5M |
| Kepos Capital LP | 3.53% | New | 210,000 | $2.1M |
| Clear Street Group Inc. | 0.01% | Reduce -29.5% | 166,642 | $1.7M |
| L1 Global Manager Pty Ltd | 0.81% | No change | 100,000 | $1.0M |
| Readystate Asset Management LP | 0.10% | No change | 100,000 | $1.0M |
| Walleye Capital LLC | 0.01% | No change | 100,000 | $1.0M |
| HRT Financial LP | 0.00% | Reduce -26.8% | 100,000 | $1.0M |
| Rangeley Capital, LLC | 0.35% | Add +70.8% | 55,612 | $327K |
| Robinson Capital Management, LLC | 0.07% | Reduce -40.0% | 15,000 | $151K |
| UBS Group AG | 0.00% | Reduce -98.1% | 1,763 | $18K |
"% of holder's portfolio" is DMIIU's weight in each manager's 13F, not the share of Drugs Made in America Acquis the manager owns.